Latest News & Features
Refine Search
Americas
If adopted, the pending rule would reshape litigation strategy and offer patent defendants a valuable tool, say Kristen Lovin and Niall Frizzell of Keker, Van Nest & Peters 29 August 2024
Careers
Former Mayer Brown partner joins White & Case, bringing experience with high-tech companies | New hire specialisms include medical devices, pharmaceuticals and chemical products. 29 August 2024
Americas
Biopharma firm sues CSPC for allegedly infringing Onivyde patent issued in August | Suit follows complaint in April asserting eight patents against Conjupro’s product. 27 August 2024
Americas
Federal magistrate proposes awarding Abbott millions of dollars from 85 companies and individuals for selling unauthorised diabetes test strips | Judge advises a permanent injunction in almost a decade old trademark case. 27 August 2024
Americas
Judges will not rehear safe harbour case between Edwards and Meril | Medtech company said court’s precedent ‘distorts the market’ for patented products. 22 August 2024
Americas
FTC backs FDA's proposals to streamline approval process for interchangeable biosimilars | Move aims to lower prescription drug costs and expand access to critical treatments | FTC emphasises the new guidance could create competition in the biologics market and save US healthcare billions of dollars. 22 August 2024
Europe
Preliminary injunction doesn't extend to Ireland because it has not ratified UPC Treaty | Case concerns dispute over patents covering continuous glucose monitoring devices used in the management of diabetes | Injunction in favour of the US market leader now applies to three markets rather than four. 20 August 2024
Europe
How much evidence is usually required to establish a prejudice at the European Patent Office, and what are the potential pitfalls in this line of argument? Stuart McKellar of EIP explores 20 August 2024
Americas
Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products. 15 August 2024
Americas
AstraZeneca successfully argued that “no reasonable jury” could find it had infringed the patents-in-suit claiming lung cancer patents | Reprieve comes after misconduct allegations against a Pfizer unit fell flat earlier this month. 15 August 2024